ChloroquineAV

Clinical Research

Gut Feelings: How Your Microbiome Quietly Governs Chloroquine's Effectiveness

Emerging science suggests that the trillions of microorganisms residing in the human gut play a surprisingly decisive role in how chloroquine is absorbed, metabolized, and ultimately experienced by the patient. For clinicians managing lupus, rheumatoid arthritis, or malaria prophylaxis, understanding this biological variable may be as important as the prescription itself. This article examines the current evidence, expert perspectives, and practical strategies for optimizing microbiome health in

Oct 15, 2026

Drug Access & Policy

Why the Same Dose of Chloroquine Produces Vastly Different Outcomes: A Pharmacogenomics Primer for Clinicians

Two patients, identical diagnoses, identical prescriptions—yet one achieves remission while the other experiences toxicity or treatment failure. Emerging research into the pharmacogenomics of chloroquine is beginning to explain this clinical puzzle, with implications for how providers personalize dosing, monitor for adverse effects, and ultimately improve outcomes across diverse patient populations.

Oct 15, 2026

Clinical Research

From Emergency Authorization to Cautionary Tale: What the Clinical Evidence on Chloroquine and COVID-19 Actually Revealed

When chloroquine emerged as a candidate COVID-19 treatment in early 2020, the collision of urgent public health need, political pressure, and incomplete science produced one of modern medicine's most instructive episodes. A rigorous review of the trial data—and the context in which it was generated—offers lasting lessons for clinicians, researchers, and patients navigating the next era of drug repurposing.

Oct 15, 2026

Drug Access & Policy

Enduring by Design: The Clinical and Economic Case for Chloroquine as a Cornerstone of Autoimmune Therapy in 2024

In an era when biologic therapies command five-figure annual price tags and pharmaceutical pipelines overflow with novel immunomodulators, chloroquine—first synthesized in 1934—continues to anchor the treatment of lupus and rheumatoid arthritis across American rheumatology practices. Its persistence is not inertia; it reflects a convergence of safety data, cost-effectiveness, and unique pharmacological properties that newer agents have yet to replicate. This analysis examines why a drug older th

Oct 15, 2026

Clinical Research

Mapping the Resistance Landscape: A Practical Guide to Chloroquine-Resistant Malaria for US Travelers and Clinicians

Chloroquine-resistant malaria strains have reshaped the global prevention and treatment calculus over the past four decades, creating real and present risks for American travelers, military personnel, and international health workers. Understanding where resistance is entrenched, where it is emerging, and how prescribing practices must adapt is no longer optional—it is a clinical imperative. This guide synthesizes current evidence to help patients and providers navigate a rapidly evolving threat

Oct 15, 2026

Drug Access & Policy

Chloroquine Through the Reproductive Lifecycle: Balancing Autoimmune Disease Control and Pregnancy Safety

For women of childbearing age managing autoimmune conditions with chloroquine, the prospect of pregnancy introduces a layered set of clinical and ethical questions with no simple answers. This article examines the current evidence base, explores how U.S. and international medical guidelines diverge on key recommendations, and outlines the decision-making frameworks that physicians and patients are using to navigate this complex intersection of disease management and reproductive health.

Oct 14, 2026

Clinical Research

Eyes Open: A Patient's Complete Guide to Retinal Monitoring During Chloroquine Therapy

Chloroquine offers meaningful therapeutic benefits for conditions ranging from malaria to lupus, but its potential impact on retinal health requires careful, ongoing surveillance. This guide walks patients through everything they need to understand about baseline eye examinations, periodic screening schedules, and the practical steps they can take to protect their vision while continuing treatment.

Oct 14, 2026

Clinical Research

Polypharmacy and Chloroquine: A Clinician's Guide to Managing High-Stakes Drug Interactions

Chloroquine's pharmacological profile creates a complex web of interactions with commonly prescribed medications, from cardiac agents to over-the-counter supplements. Understanding these interactions is not merely academic—for patients managing multiple conditions, the stakes can be dangerously high. This guide offers healthcare professionals and informed patients a structured framework for navigating polypharmacy safely.

Oct 14, 2026

Drug Access & Policy

Beyond the Prescription Label: The Expanding Off-Label Role of Chloroquine in Modern American Medicine

Decades after its FDA approval for malaria and certain autoimmune conditions, chloroquine continues to appear on prescription pads for a surprisingly wide range of diagnoses. From dermatological conditions to emerging antiviral applications, American physicians are finding clinical reasons to reach for this decades-old drug in 2024—sometimes with robust evidence behind them, and sometimes navigating genuinely contested scientific terrain.

Oct 14, 2026

Clinical Research

Antimalarials in a New Light: The Science Behind Chloroquine's Promise for Lupus, Rheumatoid Arthritis, and Beyond

Chloroquine and its derivative hydroxychloroquine have quietly become cornerstones of autoimmune disease management in the United States, even as their origins lie in tropical medicine. This article examines the pharmacological foundations, emerging clinical trial data, and practical considerations for patients and providers navigating these therapies outside their original indication.

Oct 14, 2026

Drug Access & Policy

Shortages, Supply Chains, and Systemic Gaps: The Difficult Path Chloroquine Travels to Reach American Patients

Despite decades of established use, chloroquine and hydroxychloroquine continue to face availability hurdles that leave some American patients and providers scrambling. From manufacturing concentration overseas to regional pharmacy deserts and the lingering disruptions of pandemic-era demand surges, the supply chain behind these essential medicines is more fragile than many realize.

Oct 14, 2026